CEPTAVA is a brand name for the medication known as mycophenolate mofetil, which is commonly used as an immunosuppressant. It is primarily prescribed to prevent organ rejection in patients who have undergone kidney, liver, or heart transplants. By inhibiting the proliferation of certain immune cells that can attack the transplanted organ, CEPTAVA plays a crucial role in maintaining the health and function of the transplanted organ. It is part of a class of medications known as immunosuppressive agents and works by weakening the body's immune system to help the body accept the new organ as if it were its own. Patients taking CEPTAVA must be closely monitored due to the increased risk of infection and other potential side effects associated with immunosuppression.